Overview

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt not to receive the study drug will form the control group.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Research Institute
Treatments:
Hydroxychloroquine